# Vascular dysfunction in glaucoma

> **NIH NIH R01** · STATE UNIVERSITY NEW YORK STONY BROOK · 2022 · $398,750

## Abstract

ABSTRACT
 Glaucoma, a leading cause of irreversible blindness, is characterized by progressive degeneration of the
optic nerve and retinal ganglion cells (RGC). Glaucomatous damage might be caused either by elevated
intraocular pressure (IOP), which could mechanically stress the optic nerve, or by reduced blood flow, which
could impair function of the optic nerve. Lowering IOP is the only available treatment for glaucoma, but many
patients continue to lose vision despite successful IOP reduction. Vascular abnormalities independent of IOP
can occur in glaucoma patients, such as vasospasm and hypertension. While vascular dysfunction is
associated with glaucoma pathophysiology, it remains uncertain whether blood flow impairment can be a target
for intervention. Normalizing blood flow is a compelling novel treatment strategy for glaucoma.
 Our laboratory pioneered the application of multiparametric MRI to image high-resolution lamina-specific
anatomy, quantitative blood flow, and function of the retina and optic nerve in rodents and in humans. This
includes volumetric blood flow MRI of the retina, choroid, and optic nerve head, as well as diffusion MRI to
measure optic nerve axonal integrity. Moreover, we have compelling preliminary data that blood flow is
reduced in an established animal model of glaucoma and that chronic, mild hyperoxia treatment improves
retinal function in glaucoma, supporting a role for blood flow impairment in glaucoma pathogenesis. Herein, we
will utilize our MRI methods to further investigate the role of vascular dysfunction in glaucoma pathology by
assessing a treatment to normalize blood flow in glaucoma.
 The goals of this proposal are to use our novel ocular MRI methods in an established mouse glaucoma
model to: 1) evaluate whether a novel treatment strategy to increase blood flow can prevent glaucomatous
damage and 2) evaluate whether combined treatments to lower IOP and normalize blood flow provide
additional protection against glaucomatous progression. Our central hypothesis is that blood flow dysregulation
contributes to glaucoma pathogenesis, so treatments to normalize blood flow could prevent damage and
ultimately preserve vision in glaucoma.
 The impacts of this study will be i) novel insight into glaucoma pathophysiology and into the contribution of
blood flow abnormalities to irreversible structural and functional damage, ii) establish novel retinal and optic
nerve MRI as a method that provides unique, clinically relevant information on volumetric blood flow, and iii)
establish an innovative treatment strategy for glaucoma of normalizing blood flow. The ultimate impact of this
work would be to prevent blindness and vision loss due to glaucoma.

## Key facts

- **NIH application ID:** 10364260
- **Project number:** 1R01EY032520-01A1
- **Recipient organization:** STATE UNIVERSITY NEW YORK STONY BROOK
- **Principal Investigator:** Eric Raymond Muir
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $398,750
- **Award type:** 1
- **Project period:** 2022-04-01 → 2027-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10364260

## Citation

> US National Institutes of Health, RePORTER application 10364260, Vascular dysfunction in glaucoma (1R01EY032520-01A1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10364260. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*